Adjuvant treatment of in-transit melanoma

Autor: Melissa M. de Meza, Willeke A. M. Blokx, Han J. Bonenkamp, Cristian U. Blank, Maureen J. B. Aarts, Franchette W. P. J. van den Berkmortel, Marye J. Boers‐Sonderen, Jan Willem B. de Groot, John B. Haanen, Geke A. P. Hospers, Ellen W. Kapiteijn, Olivier J. van Not, Djura Piersma, Rozemarijn S. van Rijn, Marion A. Stevense‐Den Boer, Astrid A. M. van der Veldt, Gerard Vreugdenhil, Alfons J. M. van den Eertwegh, Karijn P. M. Suijkerbuijk, Michel W. J. M. Wouters

Publikováno v: International Journal of Cancer, 153, 2, pp. 389-398
de Meza, M M, Blokx, W A M, Bonenkamp, H J, Blank, C U, Aarts, M J B, van den Berkmortel, F W P J, Boers-Sonderen, M J, de Groot, J W B, Haanen, J B, Hospers, G A P, Kapiteijn, E W, van Not, O J, Piersma, D, van Rijn, R S, Stevense-den Boer, M A, van der Veldt, A A M, Vreugdenhil, G, van den Eertwegh, A J M, Suijkerbuijk, K P M & Wouters, M W J M 2023, ' Adjuvant treatment of in-transit melanoma : Narrowing the knowledge gap left by clinical trials ', International Journal of Cancer, vol. 153, no. 2, pp. 389-398 . https://doi.org/10.1002/ijc.34485
International Journal of Cancer, 153(2), 389-398. Wiley-Liss Inc.
International Journal of Cancer, 153, 389-398
International Journal of Cancer. Wiley
International Journal of Cancer, 153, 389-398. Wiley

Contains fulltext : 292870.pdf (Publisher’s version ) (Open Access) Few clinical trials address efficacy of adjuvant systemic treatment in patients with in-transit melanoma (ITM). This study describes adjuvant systemic therapy of ITM patients beyon

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::93a86c7bb4276a536cc2f402f2c073ca
http://www.scopus.com/inward/record.url?scp=85150473429&partnerID=8YFLogxK

Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma

Autor: Maartje W. Rohaan, Troels H. Borch, Joost H. van den Berg, Özcan Met, Rob Kessels, Marnix H. Geukes Foppen, Joachim Stoltenborg Granhøj, Bastiaan Nuijen, Cynthia Nijenhuis, Inge Jedema, Maaike van Zon, Saskia Scheij, Jos H. Beijnen, Marten Hansen, Carlijn Voermans, Inge M. Noringriis, Tine J. Monberg, Rikke B. Holmstroem, Lidwina D.V. Wever, Marloes van Dijk, Lindsay G. Grijpink-Ongering, Ludy H.M. Valkenet, Alejandro Torres Acosta, Matthias Karger, Jessica S.W. Borgers, Renske M.T. ten Ham, Valesca P. Retèl, Wim H. van Harten, Ferry Lalezari, Harm van Tinteren, Astrid A.M. van der Veldt, Geke A.P. Hospers, Marion A.M. Stevense-den Boer, Karijn P.M. Suijkerbuijk, Maureen J.B. Aarts, Djura Piersma, Alfons J.M. van den Eertwegh, Jan-Willem B. de Groot, Gerard Vreugdenhil, Ellen Kapiteijn, Marye J. Boers-Sonderen, W. Edward Fiets, Franchette W.P.J. van den Berkmortel, Eva Ellebaek, Lisbet R. Hölmich, Alexander C.J. van Akkooi, Winan J. van Houdt, Michel W.J.M. Wouters, Johannes V. van Thienen, Christian U. Blank, Aafke Meerveld-Eggink, Sebastian Klobuch, Sofie Wilgenhof, Ton N. Schumacher, Marco Donia, Inge Marie Svane, John B.A.G. Haanen

Publikováno v: New England Journal of Medicine, 387(23), 2113-2125. MASSACHUSETTS MEDICAL SOC
The New England Journal of Medicine, 387, 2113-2125
New England journal of medicine, 387(23), 2113-2125. Massachussetts Medical Society
Rohaan, M W, Borch, T H, Van Den Berg, J H, Met, Ö, Kessels, R, Geukes Foppen, M H, Stoltenborg Granhøj, J, Nuijen, B, Nijenhuis, C, Jedema, I, Van Zon, M, Scheij, S, Beijnen, J H, Hansen, M, Voermans, C, Noringriis, I M, Monberg, T J, Holmstroem, R B, Wever, L D V, Van Dijk, M, Grijpink-Ongering, L G, Valkenet, L H M, Torres Acosta, A, Karger, M, Borgers, J S W, Ten Ham, R M T, Retèl, V P, Van Harten, W H, Lalezari, F, Van Tinteren, H, Van Der Veldt, A A M, Hospers, G A P, Stevense-Den Boer, M A M, Suijkerbuijk, K P M, Aarts, M J B, Piersma, D, Van Den Eertwegh, A J M, De Groot, J W B, Vreugdenhil, G, Kapiteijn, E, Boers-Sonderen, M J, Fiets, W E, Van Den Berkmortel, F W P J, Ellebaek, E, Hölmich, L R, Van Akkooi, A C J, Van Houdt, W J, Wouters, M W J M, Van Thienen, J V, Blank, C U, Meerveld-Eggink, A, Klobuch, S, Wilgenhof, S, Schumacher, T N, Donia, M, Svane, I M & Haanen, J B A G 2022, ' Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma. ', New England Journal of Medicine, vol. 387, no. 23, pp. 2113-2125 . https://doi.org/10.1056/NEJMoa2210233
The New England journal of medicine, 387(23), 2113-2125. Massachussetts Medical Society
New England Journal of Medicine, 387(23), 2113-2125. MASSACHUSETTS MEDICAL SOCIETY
The New England Journal of Medicine, 387, 23, pp. 2113-2125

Item does not contain fulltext BACKGROUND: Immune checkpoint inhibitors and targeted therapies have dramatically improved outcomes in patients with advanced melanoma, but approximately half these patients will not have a durable benefit. Phase 1-2 tr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::edf28a71e5a16116e2b0f59cdac9485a
https://research.rug.nl/en/publications/9033fdbd-9e6f-4cca-a35b-50890da9f292

End-of-Life Use of Systemic Therapy in Patients With Advanced Melanoma: A Nationwide Cohort Study

Autor: Jesper van Breeschoten, Rawa K. Ismail, Michel W.J.M. Wouters, Doranne L. Hilarius, Liesbeth C. de Wreede, John B. Haanen, Christian U. Blank, Maureen J.B. Aarts, Franchette W.P.J. van den Berkmortel, Jan Willem B. de Groot, Geke A.P. Hospers, Ellen Kapiteijn, Djura Piersma, Rozemarijn S. van Rijn, Marion A. Stevense-den Boer, Astrid A.M. van der Veldt, Gerard Vreugdenhil, Marye J. Boers-Sonderen, Karijn P.M. Suijkerbuijk, Alfons J.M. van den Eertwegh

Publikováno v: JCO oncology practice, 18(10):e1611
JCO Oncology Practice, 18(10), e1611-e1620. American Society of Clinical Oncology
None
JCO oncology practice, 18(10), e1611-e1620. Lippincott Williams and Wilkins Ltd.
van Breeschoten, J, Ismail, R K, Wouters, M W J M, Hilarius, D L, de Wreede, L C, Haanen, J B, Blank, C U, Aarts, M J B, van den Berkmortel, F W P J, de Groot, J W B, Hospers, G A P, Kapiteijn, E, Piersma, D, van Rijn, R S, Stevense-den Boer, M A, van der Veldt, A A M, Vreugdenhil, G, Boers-Sonderen, M J, Suijkerbuijk, K P M & van den Eertwegh, A J M 2022, ' End-of-Life Use of Systemic Therapy in Patients With Advanced Melanoma : A Nationwide Cohort Study ', JCO oncology practice, vol. 18, no. 10, pp. e1611-e1620 . https://doi.org/10.1200/OP.22.00061
JCO Oncology Practice, 18, 10, pp. e1611-e1620
JCO Oncology Practice, 18(10), e1611-e1620. LIPPINCOTT WILLIAMS & WILKINS
JCO Oncology Practice, 18, e1611-e1620

PURPOSE: The introduction of immune checkpoint inhibitors and targeted therapies improved the overall survival of patients with advanced melanoma. It is not known how often these costly treatments with potential serious side effects are ineffectively

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f4f55afe4f56e5455e1d09504604d862
https://hdl.handle.net/2066/290170

Population Mortality in Advanced Melanoma Patients with and Without Response and Progression; Data from the Dutch Melanoma Treatment Registry

Autor: Jesper van Breeschoten, Alfons J.M. van den Eertwegh, Doranne L. Hilarius, John Haanen, Christian U. Blank, Maureen J.B. Aarts, Franchette W.P.J. van den Berkmortel, Jan Willem B. de Groot, Geke A.P. Hospers, Ellen Kapiteijn, Djura P. Piersma, Rozemarijn S. van Rijn, Marion A. Stevense-den Boer, Gerard Vreugdenhil, Marye J. Boers-Sonderen, Damjan Manevski, Karijn P.M. Suijkerbuijk, Michel W.J.M. Wouters, Liesbeth C. de Wreede

Publikováno v: SSRN Electronic Journal.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6747168b73a73f7153ae727b5f6d5cd9
https://doi.org/10.2139/ssrn.4267708